Table 1 The key reported clinical trials of of PD-1/PD-L inhibitors in patients with esophageal cancer
Tumor type | Target | Drug | Phase and identification | Sample size | Clinical end point | TRAEs | Reference |
|---|---|---|---|---|---|---|---|
EC | PD-1 | Nivolumab | Phase II JapicCTI-142422 | 64 | ORR 17% (central assessment), 22% (investigator assessment); DCR 42% (central assessment), 53% (investigator assessment) | All grade 60%, including diarrhea, decreased appetite, lung infection, rash, fatigue; grade ≥3 17%, including decreased appetite, lung infection, blood creatinine phosphokinase increased, dehydration | Lancet Oncology 2017 [133] |
EC | PD-1 | Nivolumab | Phase II JapicCTI-142422 | 64 | ORR 17.2%; SD 25.0%; median OS 12.1Â m | Drug-related serious AEs 13.8%, including lung infection, dehydration, interstitial lung disease | ASCO 2016 [29] |
EC | PD-1 | Pembrolizumab | Phase I NCT02054806 | 23 | ORR 30.4%; SD 13.0%; 6-month PFS rate 30.4%; 12-month PFS rate 21.7% | All grade 39.1%, including decreased appetite; grade 3 26%, including decreased lymphocytes | ASCO 2016 [28] |
EC | PD-1 | Pembrolizumab | Phase Ib NCT02054806 | 23 | ORR 23%; SD 18%; PD 59% | All grade 26%; grade 3 9% | ASCO 2015 [151] |